Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.74
Price-To-Earnings
Trailing P/E Ratio-3.98
Forward P/E Ratio-4.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$57.63 million
Price / Sales3.35
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book2.76
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-28,150,000.00
Net Margins-46.62%
Return on Equity-57.49%
Return on Assets-28.83%
Miscellaneous
Employees323
Outstanding Shares55,550,000
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?
Avid Bioservices declared a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date is Friday, March 16th. View Avid Bioservices' Dividend History.
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Shares of Avid Bioservices reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices (NASDAQ:CDMO) announced its quarterly earnings data on Monday, March, 12th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.09. The biopharmaceutical company had revenue of $6.82 million for the quarter, compared to analysts' expectations of $8.95 million. Avid Bioservices had a negative return on equity of 57.49% and a negative net margin of 46.62%. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What price target have analysts set for CDMO?
4 brokerages have issued 12 month target prices for Avid Bioservices' stock. Their predictions range from $4.00 to $10.00. On average, they expect Avid Bioservices' share price to reach $6.3333 in the next twelve months. View Analyst Ratings for Avid Bioservices.
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include NuCana (NCNA), ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), Inflarx (IFRX), Urogen Pharma (URGN), Vectura Group (VEGPF), Geron (GERN), Homology Medicines (FIXX), Odonate Therapeutics (ODT), Arcus Biosciences (RCUS), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA) and Evolus (EOLS).
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Mr. Paul J. Lytle, CFO & Principal Accounting Officer (Age 50)
- Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 54)
- Dr. Shelley P. M. Fussey Ph.D., VP of Intellectual Property (Age 52)
- Ms. Tracy L. Kinjerski, VP of Bus. Operations
- Dr. Steven M. Chamow, Head of Technical Services (Age 64)
Has Avid Bioservices been receiving favorable news coverage?
Media headlines about CDMO stock have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Avid Bioservices earned a news impact score of 0.06 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Avid Bioservices' major shareholders?
Avid Bioservices' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bandera Partners LLC (1.84%), BlackRock Inc. (1.37%), CVI Holdings LLC (1.07%), Schwartz Investment Counsel Inc. (0.86%), Wells Fargo & Company MN (0.40%) and Stifel Financial Corp (0.34%). View Institutional Ownership Trends for Avid Bioservices.
Which institutional investors are buying Avid Bioservices stock?
CDMO stock was purchased by a variety of institutional investors in the last quarter, including Bandera Partners LLC, BlackRock Inc., CVI Holdings LLC, Schwartz Investment Counsel Inc., Wells Fargo & Company MN, Stifel Financial Corp, Millennium Management LLC and Northern Trust Corp. View Insider Buying and Selling for Avid Bioservices.
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $3.48.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $201.10 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Avid Bioservices employs 323 workers across the globe.
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
